Head-to-head · WeighScore
Invigor Medical vs Valhalla Vitality
By GLP-1 ScorecardUpdated
Score comparison
Invigor Medical has the higher recorded score — 86.1/100 to 63.6/100.
Invigor Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Now Try Invigor, this platform advertises class-based GLP-1 plans; confirm your medicine and supply before accepting its starting price.
Before you choose
Before comparing the headline prices, the Invigor Medical review and the Valhalla Vitality review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Invigor Medical vs VevaRX and Mojoon vs Valhalla Vitality compare each of them with another graded program, and the list of alternatives to Invigor Medical ranks the programs closest to Invigor Medical on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Direct Meds review covers one graded close to these two, at 77.6/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Invigor Medical | Valhalla Vitality |
|---|---|---|
| WeighScore | 86.1/100 | 63.6/100 |
| Grade | B | C |
| Site position | #9 | #273 |
| Semaglutide | Medication-specific quote unconfirmed; public GLP-1 treatment starts at $225. | Not disclosed by drug (site lists injectable GLP-1 from $99; product prices require sign-in) |
| Tirzepatide | Medication-specific quote unconfirmed; public GLP-1 + GIP treatment starts at $350/month. | Not disclosed by drug (site lists injectable GLP-1 from $99; product prices require sign-in) |
| Coverage | U.S. only; confirm medication-specific state availability | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Consultation, medication and supplies advertised together
- Ordinary and microdose treatment listings are separately presented
- Clinical policy describes virtual consultation and relevant testing when needed
What to consider
- Current medication-specific dose and supply quote is unconfirmed
- Cancel new orders before the prescription enters the practitioner's queue
- Subscriptions need seven days’ notice before renewal processing; charges may occur early
- No universal GLP-1 lab panel, frequency or separate testing price published
Strengths
- LegitScript-certified pharmacy partner
- Offers both compounded semaglutide and tirzepatide
- No membership fees and free consultations
- Add-on peptide and hormone therapies plus at-home labs
What to consider
- Compounded GLP-1 only, no FDA-approved branded options
- Pricing not transparently listed on the main site
- Compounded drugs are not FDA-approved for safety or efficacy
- States served not clearly disclosed
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.